DW 908e

Drug Profile

DW 908e

Alternative Names: DW-908e

Latest Information Update: 12 May 2008

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Carboxylic acids; Indoles; Pyrrolidines
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 12 May 2008 Discontinued - Phase-I for Asthma in Japan (PO)
  • 12 May 2008 Discontinued - Phase-I for Asthma in USA (PO)
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top